Compare iShares MSCI South Africa ETF (EZA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Novartis AG — how do they compare? iShares MSCI South Africa ETF trades at $62.57 (market cap $466.20M), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 587.7× iShares MSCI South Africa ETF's market cap, and Novartis AG pays a 3.31% dividend while iShares MSCI South Africa ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 70 Days and Novartis AG for 82 Days on average.
| EZA | NVS | |
|---|---|---|
Market Cap | $466.20M | $274.00B |
Volume | 152,369 | 1,852,137 |
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $168.62 |
52-Week Low | $60.43 | $121.80 |
Typical Hold Time | 70 Days | 82 Days |
Enterprise Value | — | $315.32B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $62.29, down 2.15% today, with a bearish technical signal driven by moving averages. The ETF's portfolio faces headwinds from global reflation impacting its heavy exposure to South African gold, banking, and platinum group metals. Key oscillators like the 6-day and 12-day relative strength index indicate oversold conditions, suggesting potential for a near-term bounce, but the average directional index signals a strong downtrend.
The outlook is cautious due to macroeconomic pressures on constituent companies, with risks from higher capital costs and commodity price volatility. Investment opportunity hinges on a reversal in global yield curves and commodity markets, but current sentiment remains negative amid sell-side dominance and lack of positive fundamental catalysts.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
